Waiting for news may be more interesting than the news itself, and there is some serious waiting with bated breath for news from DiaDexus, Inc. (OTCMKTS:DDXS). DDXS added about 5% on Friday to reach...
If you like the idea of overhanging disaster, then pharmaceutical stocks are the right choice. Fueled by hope, and immediately cut down when a drug does not receive a green light- yet another time...
A week more, and Liberator Medical Holdings, Inc. (OTCMKTS:LBMH) is still going strong, although Monday came with zero gain for the price. Still, dollar volumes reached $1.6 million, and nearly a million shares were...
When a company makes a streak of near-record volumes, and spikes by 300% in mere days, it deserves attention, but mostly-caution. AmpliPhi Biosciences Corporation (OTCMKTS:APHB) is rising without the benefit of either paid promotions...
Aethion Medical (OTCBB:AEMD) is moving according to the logic for biopharmaceutical companies. The promise of a new drug or treatment approaching market is always a cause to boost the stock. A free promotion from...
InVivo Therapeutics Holding (OTCBB:NVIV) is going through a sensitive period, correcting a very strong climbing trend. Friday marked the ticker’s first day of net buying after three days of selling. A bit more than...
Invivo Therapeutics Holdings, Corp. (OTCBB:NVIV) is on yet another upward run, a part of a bigger bullish trend started at the beginning of the year. It seems 2013 means more activity for yet another...
Celsion, Corp. (NASDAQ:CLSN) is yet another ambitions biotechnological company cut short by a sudden reversal of fortune. Just on the verge of a stage III trial with expected positive outcomes, CLSN crashed from $4.30...
Pharmaceutical stocks are a fragile thing. Most companies show long-term potential and impress with a great development story. But in the case of Titan Pharmaceuticals, Inc. (OTCBB:TTNP) it takes a small event to tip...
A long-embattled ticker, Amarantus Biosciences, Inc. (OTC:AMBS) , is charting a small rising trend in the past days, adding nearly a third to its price on healthy volumes, nearing 8 cents. The success of...